The Journal is Indexed in
2 - Additional acarbose therapy to other group of oral antidiabetics provides metabolic control in the first 6 weeks
Sema Uçak, Okcan Basat, Selçuk Şeber, Özdal Ersoy, Ahmet Şengül, Akın Kürklü, Taner Baştürk, Yüksel Altuntaş
Objective: Acarbose primarily inhibits the post prandial blo¬od sugar surge, so that the toxic effects of glucose on insulin resistance and the beta-cell function is reduced or prevented. We tried to evaluate the short term effects of additional acar¬bose treatment on metabolic control.
Study Design: Patients with poor metabolic control (HbAlc values between 7-10 nmol/L) under therapy were includucd in the study. An acarbose 3x100mg/day fgroup 1, n=!00) or placebo (group 2, n=30) therapy was added to their previous therapies. Patients were followed up for 12 weeks. Baseline to week 6 and week 12 in HbAlc, c-Pepticle, immunoreactive insuline, body mass index (BMI) and serum lipids were me¬asured.
Results: In group 1, additional acarbose therapy reduced HbAlc from baseline by 1.54 percentage points (p<().()()I ). C- Peptide and insulin levels signifantly reduced at week 6 (p<0.05). This reduction maintained at week 12. In group 2 this reduction was not observed
Conclusion: The data from this study show that additional acarbose therapy provides a good metabolic control and beneficial effects on insulin resistance even in short term in type 2 diabetic patients who previously received oral antidiabetic drugs.
Keywords: Acarbose, metabolic control, type 2 diabetes melitus
To read full article click